Cellectis (NASDAQ:CLLS) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a buy rating in a research report report published on Monday morning.

Cellectis Stock Performance

Shares of NASDAQ:CLLS opened at $1.24 on Monday. The business’s 50-day simple moving average is $1.42 and its 200 day simple moving average is $1.73. The company has a market cap of $68.92 million, a P/E ratio of -0.95 and a beta of 3.27. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. Cellectis has a one year low of $1.14 and a one year high of $3.38.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $33.22 million for the quarter, compared to analysts’ expectations of $5.90 million. On average, sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 12,500 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Cellectis in the fourth quarter worth about $962,000. Finally, B Group Inc. purchased a new position in Cellectis in the fourth quarter valued at about $5,547,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.